

Press release

IMCD China strengthens its life science business with the acquisition of Daoqin

ROTTERDAM, The Netherlands (13 December 2024) – IMCD N.V. ("IMCD" or "Company"), a global leading distribution partner and formulator of speciality chemicals and ingredients, today announces that IMCD has signed an agreement to acquire the business of the food and nutraceutical ingredient distributor: Daoqin Biological Technology (Shanghai) Co., Ltd., Longyu International Trade (Shanghai) Co., Ltd. and Long'en Biotechnology (Guangzhou) Co., Ltd. in China (jointly "Daoqin").

Established in 2011, Daoqin specialises in the distribution of functional nutrition, nutraceutical and food ingredients. Daoqin represents leading suppliers and offers, through its dedicated technical team and its laboratory, innovative solutions to its customers in the food, personal care and pharmaceutical industries. Daoqin is headquartered in Shanghai, China, and generated a revenue of approximately CNY 122 million (ca. EUR 16 million) in 2023 with 21 employees.

"The addition of Daoqin marks another step in our journey to deepen our presence in the food and nutrition markets and broadens the scope of our life science business portfolio," remarked Nicky Huang, Managing Director of IMCD China. "With the acquisition of Daoqin, we are very excited to welcome a very engaged and talented team and leverage our complementary portfolios and technical expertise to enhance our capabilities and offering in the local market," concluded Huang.

"The Daoqin team is excited to join IMCD, as we believe there are strong synergies between our businesses and capabilities," said Jack Ning, General Manager of Daoqin. "By leveraging IMCD's exceptional global network and resources, we look forward to bringing greater innovation and value to customers in the life sciences markets in China."

The closing of the transaction is subject to customary closing conditions and is expected to take place in the second quarter of 2025.

- xxx -

About IMCD N.V.

IMCD N.V. based in Rotterdam, The Netherlands, is a leading global distribution partner and formulator of speciality chemicals and ingredients. A strong, innovative business partner and solutions provider for producers of consumer, industrial and durable goods in multiple business sectors: advanced materials, beauty and personal care, coatings and construction, food and nutrition, home, industrial and institutional care, industrial solutions, lubricants and energy, and pharmaceuticals.

In partnership with our suppliers, we offer a broad and deep product portfolio. In over 70 application laboratories, we co-create formulations and sustainable solutions that allow our business partners to make products with a positive impact on the world of today and tomorrow. Our teams focus on providing commercial and operational excellence, using the best digital and logistics tools available to create a world of opportunity for our partners.

In 2023, with over 4700 employees, IMCD realised a revenue of EUR 4,443 million. IMCD N.V.'s shares are traded at Euronext, Amsterdam (symbol: IMCD) and included in the Dutch ESG AEX index, as one of 25 companies within the AEX and AMX indices demonstrating best ESG practices.

For further information, please visit www.imcdgroup.com.

Media contacts

IMCD Media Centre
mediarelations@imcdgroup.com

IMCD Group
Muriel Werlé
muriel.werle@imcdgroup.com

IMCD APAC
Wendi Lim
+65 6995 1026
wendi.lim@imcd.sg

[CN Version]

IMCD 中国通过收购道勤加强其生命科学业务

荷兰鹿特丹（2024 年 12 月 13 日） - IMCD N.V.（以下简称“IMCD”或“公司”），全球领先的特种化学品和辅料分销合作伙伴及配方供应商，今天宣布 IMCD 已签署协议收购食品和营养品配料分销商的业务：道勤生物科技（上海）有限公司、珑宇国际贸易（上海）有限公司和珑恩生物科技（广州）有限公司（合称“道勤”）。

道勤成立于 2011 年，专注于从事功能性营养品和食品配料的分销业务。道勤代理领先的供应商产品，并通过其专业的技术团队和实验室，为食品、个人护理和制药行业的客户提供创新解决方案。道勤总部位于中国上海，2023 年收入约为 1.22 亿人民币（约合 1600 万欧元），拥有 21 名员工。

道勤的加入标志着 IMCD 在深化食品和营养品市场业务的道路上又迈出了一步，同时也拓宽了我们生命科学业务组合的范围，IMCD 中国区董事总经理黄丽敏表示，“通过收购道勤，我们非常高兴地迎来了一支敬业、人才济济的团队，并利用我们互补的产品组合和技术专长，增强我们在本地市场的能力和组合。”

道勤总经理宁浩强表示：“今天我们非常高兴能加入 IMCD 集团。道勤生物科技始终坚持：链接全球最优资源，为中国生命科学企业持续提供产品创新解决方案。IMCD 集团以其卓越的全球网络和资源，与我们的愿景不谋而合。此次强强联合，更是我们共同致力于推动大健康行业向更高品质、更安全美味的方向发展的开始。我们期待通过这次合并，为客户带来更多创新和价值，共同开启营养健康新纪元。”

交易的完成取决于惯例成交条件，预计将于 2025 年第二季度完成。

- 关于 IMCD N.V.

IMCD 集团，总部位于荷兰鹿特丹，是全球领先的特种化学品和辅料的分销合作伙伴及配方提供商。IMCD 是强大且创新的商业伙伴和解决方案提供商，为以下多个领域的消费品、工业品和耐用品的生产商提供解决方案：先进材料，美容与个人护理，涂料与建筑，食品与营养品，家庭护理与工业防护，工业解决方案，润滑与能源，医药。

我们与供应商合作，提供广泛而深入的产品组合。在 70 多个应用实验室中，我们与合作伙伴共同设计配方和可持续解决方案，使我们的业务合作伙伴能够生产对当今世界和未来都有积极影响的产品。我们的团队专注于提供卓越商业运营，使用现有的最佳数字化工具和物流工具为我们的合作伙伴创造一个充满机遇的世界。

2023 年，IMCD 拥有 4700 多名员工，实现收入 44.43 亿欧元。

IMCD NV 在阿姆斯特丹泛欧交易所上市（股票代码：IMCD），并被纳入荷兰 ESG AEX 指数，是 AEX 和 AMX 指数中展示最佳 ESG 实践的 25 家公司之一。

了解更多信息，请访问 www.imcdgroup.com。

媒体联系

IMCD 媒体中心

mediarelations@imcdgroup.com

IMCD 集团

Muriel Werl

muriel.werle@imcdgroup.com

IMCD 亚太区

Wendi Lim

+65 6995 1026

wendi.lim@imcd.sg